Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.38 CAD | +1.71% | +4.85% | +466.67% |
05-22 | Medicenna to Present Clinical Update on MDNA11 ABILITY-1 Trial at Sachs Oncology Innovation Forum | MT |
05-13 | Medicenna Says ABILITY-1 Abstract Withdrawn by ASCO Program Committee | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+466.67% | 128M | |
+69.01% | 62.86B | |
-0.81% | 41.38B | |
+45.66% | 40.38B | |
-10.72% | 27.64B | |
+14.53% | 26.46B | |
-21.92% | 18.9B | |
+4.48% | 12.67B | |
+24.74% | 12.27B | |
+28.21% | 12.07B |
- Stock Market
- Equities
- MDNA Stock
- News Medicenna Therapeutics Corp.
- Medicenna on Appointment of Clinical Advisory Board and Dr. Kapil Dhingra as Strategic Advisor; Chief Scientific Officer Departs